Clinical trials: Female Osteoporosis
Osteoporosis in Post-menopausal Women
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Osteoporosis is associated with a high risk of fractures, disability, loss of independence, and excess mortality. Zoledronic acid is an established first-line treatment in Sweden, but many patients at high fracture risk remain at…
- Trial name
- STRONG-HIP (NCT07772609)
- Testing
- Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU
- Where
- 9 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Sahlgrenska University Hospital
Atypical Femoral Fractures, Osteoporosis
Exome Sequencing for Atypical Femoral Fractures
The purpose of this study is to determine whether women who have atypical subtrochanteric and diaphyseal femoral fractures after treatment with bisphosphonates for osteoporosis, have a genetic predisposition to these unusual…
- Conditions
- Atypical Femoral Fractures, Osteoporosis, Bisphosphonate Therapy
- Trial name
- NCT02731040
- Testing
- Bisphosphonate
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Osteoporosis, Postmenopausal
A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)
The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.
- Trial name
- NCT00092040
- Testing
- MK0217, alendronate sodium/Duration of Intervention: 12 mo, Comparator: risedronate / Duration of Intervention: 12 mo
- Volunteers
- 936 people
- Sponsor
- Organon and Co
Osteoporosis
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
1. The study will assess the safety and tolerability of a single-infusion of zoledronic acid 5 mg administered in a private medical practice setting by a nurse provided by a nationwide infusion service.
- Trial name
- LISA (NCT00745485)
- Testing
- zoledronic acid
- Where
- 14 sites in Australia
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Denosumab Safety Assessment in Multiple Observational Databases
This is a prospective open-cohort study with annual assessment and reporting of descriptive findings from 5 secondary data sources, US Medicare, Optum Research Database (formerly United HealthCare), Scandinavian national health…
- Trial name
- NCT02520362
- Testing
- denosumab, bisphosphonate
- Volunteers
- 517,991 people
- Sponsor
- Amgen
Breast Cancer, Menopause
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
Aromatase inhibitor therapy is in France the adjuvant reference treatment for postmenopausal women with early-stage breast cancer. This treatment induces bone loss and a higher risk of fractures.
- Conditions
- Breast Cancer, Menopause, Osteopenia
- Trial name
- RISAROS (NCT00859703)
- Testing
- Risedronate
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Osteoporosis
The Relationship Between the Residual Renal Function and Osteoporosis Treatment
The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.
- Trial name
- NCT02304887
- Testing
- Bis, SERM Teriparatide, Denosumab
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Toshihiko Kono
Osteoporosis
Effect of Sodium Intake on Calcium Retention in Girls
Optimal calcium retention is important for building bone mass within the genetic potential, a key to reducing risk of osteoporosis later in life. Calcium retention is high during the rapid growth period.
- Trial name
- NCT01564238
- Testing
- Low Na diet (1.3 g/d), High sodium diet (3.8 g/d)
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Purdue University
Osteoporosis
Study Evaluating Changes In Mammographic Breast Density
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg…
- Trial name
- NCT00774267
- Testing
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 507 people
- Sponsor
- Pfizer
Depression, Healthy
Bone Loss in Premenopausal Women With Depression
The purpose of this study is to determine whether women with major depression lose bone mass at a faster rate than women without depression.
- Conditions
- Depression, Healthy, Osteopenia, Osteoporosis
- Trial name
- NCT00006180
- Testing
- Alendronate
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Osteoporosis, Bone Loss
Romosozumab in Women With Chronic SCI
This two-year open-label pilot clinical trial will evaluate the efficacy and safety of romosozumab to treat bone loss in females with chronic spinal cord injury (SCI) and osteoporosis (OP).
- Conditions
- Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries
- Trial name
- NCT04708886
- Testing
- Romosozumab, Alendronate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Osteoporosis, Post-Menopausal
Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population
- Trial name
- NCT00532545
- Testing
- Teriparatide
- Where
- 7 sites in Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Osteoporosis, Cardiovascular Risk Factor
Effects of a 12-week Home-based Yoga on Bone and Cardiovascular Health
While effects of specific exercise interventions on bone and CVD in postmenopausal women have been demonstrated and evaluated, the effects of randomized controlled exercise interventions, particularly in middle-aged premenopausal…
- Trial name
- NCT04353700
- Testing
- Yoga group
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Lowell
Breast Neoplasms, Bone Loss
Bone Loss Treatment From Adjuvant Zoledronate Efficacy
The main purpose of this study is to observe and assess the impact of adjuvant zoledronate on bone density in breast cancer patients.
- Trial name
- BLAZE (NCT01623908)
- Testing
- Zoledronate
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Osteoporotic Fractures, Spinal Fractures
Build Better Bones With Exercise
The long-term goal of our research team is to conduct a large multicentre study to evaluate whether tailored home exercise can prevent fractures in high-risk individuals.
- Trial name
- B3E (NCT01761084)
- Testing
- Exercise and behaviour change strategies
- Where
- Canada
- Volunteers
- 141 people
- Sponsor
- University of Waterloo
Breast Cancer, Osteoporosis
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.
- Trial name
- NCT00767585
- Where
- Slovenia
- Volunteers
- 560 people
- Sponsor
- AstraZeneca
Osteoporosis
A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)
The study will evaluate the both the efficacy of odanacatib on Bone Mineral Density (BMD) and the safety of odanacatib for postmenopausal osteoporosis in patients previously treated with alendronate.
- Trial name
- NCT00885170
- Testing
- Odanacatib, Vitamin D3, Calcium
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis in Postmenopausal Women
Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)
Primary objective: To compare the bone mineral density (BMD) change under the treatment of denosumab with eldecalcitol or native vitamin D in postmenopausal women with osteoporosis on bone mineral density.
- Trial name
- ESCORT (NCT05884372)
- Testing
- Eldecalcitol, Native Vitamin D, Denosumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xi'an Honghui Hospital
Postmenopausal Osteoporosis
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were…
- Trial name
- STRUCTURE (NCT01796301)
- Testing
- Romozosumab, Teriparatide
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 436 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Study of Transitioning From Alendronate to Denosumab
The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab.
- Trial name
- NCT00377819
- Testing
- alendronate, Denosumab (AMG 162)
- Volunteers
- 504 people
- Sponsor
- Amgen